BG Medicine has entered an agreement with Boston Scientific allowing the latter to use its galectin-3 test for heart failure to pinpoint patients who might be candidates for a cardiac resynchronization treatment. The deal will allow Boston Scientific to use BG's biomarker discovery technologies to identify other biomarkers that could help predict patients' responses to the therapy.

Related Summaries